Although PRODIGE-7 had us saying BYE-PEC to hyperthermic intraperitoneal chemo (HIPEC) for colorectal cancer carcinomatosis, this South Korean prospective randomized trial reports an overall survival advantage when used at interval (as opposed to upfront) cytoreductive surgery following neoadjuvant systemic therapy for ovarian cancer carcinomatosis. | Lim, JAMA Surg 2022


Popular Posts